BiotechTube
Home/Syngle Therapeutics/Victor van Koolwijk
VV

Victor van Koolwijk

Chief Financial Officer

Syngle Therapeutics

Therapeutic Areas

Parkinson's DiseaseSynucleinopathies

Syngle Therapeutics Pipeline

DrugIndicationPhase
26F1 AAV Gene TherapyParkinson's DiseasePreclinical

Leadership Team at Syngle Therapeutics

GS
Guus Scheefhals
Chief Executive Officer
DB
Dr. Bas Blits
Head of R&D / CSO (implied)
View full Syngle Therapeutics profile